PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|October 1, 2018
Call for Entries: Eppendorf’s Award for Young European Investigators 2019
Author(s)Pharmaceutical Technology Editors
Researchers who are younger than 35 years with an advanced degree and working within Europe will be able to apply for the award.
Advertisement
Life-science company Eppendorf has announced it is now taking applications for its 2019 Award for Young European Investigators. From Oct. 1, 2018 until Jan. 15, 2019, researchers who are younger than 35 years with an advanced degree and working within Europe will be able to apply for the award.
First established in 1995, the Eppendorf Award for Young European Investigators acknowledges outstanding contributions to biomedical research based on methods of molecular biology, including novel analytical concepts. It is presented in partnership with the scientific journal
The winner, once selected by an independent expert committee-chaired by Reinhard Jahn (Max Planck Institute for Biophysical Chemistry, Göttingen, Germany)-will be awarded €20,000 (approx. US$23,000) prize money. The winning work will be included within the print and online versions of the journal Nature, including a podcast. Additionally, the winner will be invited to a prize ceremony at the European Molecular Biology Laboratory (EMBL) Advanced Training Centre in Heidelberg, Germany, on Jun. 27, 2019, and invited to visit Eppendorf’s facility in Hamburg, Germany.
Applications for this award will only be accepted through Eppendorf’s online registration portal, which can be found at
Source: Eppendorf
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement